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Materials and Methods 
Mice 
C57BL/6 mice were purchased from Taconic Farms. Nod2-/- mice were purchased from 
the Jackson Laboratory. Atg16l1fl/fl Cd11c-Cre-/- (WT), Atg16l1fl/fl Cd11c-Cre+/- 
(Atg16L1ΔCD11c), Atg16l1fl/fl LysM-Cre, Atg5fl/fl LysM-Cre, Atg7fl/fl LysM-Cre, Atg14fl/fl 
LysM-Cre, Fip200fl/fl LysM-Cre mice and femurs were obtained from H. W. Virgin (42, 
43), ATG16L1 T300A mice from R. J. Xavier (22), and Ulk1-/- and Rubicon-/- mice and 
femurs from M. Kundu (44) and D. R. Green (35) under a materials transfer agreement 
with St. Jude Children’s Research Hospital, respectively. For all studies performed with 
Cre-floxed mice, the Cre-/- littermates served as wildtype controls. 8-10 week old sex-
matched mice were used in the study. All procedures were performed in accordance with 
the guidelines and approved protocols from the Institutional Animal Care and Use 
Committee at the California Institute of Technology. 
 
Human peripheral blood mononulear cells  
Crohn’s disease subjects were recruited from the IBD Center at Cedars-Sinai Medical 
Center following informed consent and IRB approval. ATG16L1 genotyping was 
performed using the Immunochip (Illumina, San Diego, CA, USA) according to the 
manufacturer’s instructions and as previously described (10). Patient sample information 
is described in Supplemental Table 1. 
 
Bacterial strains, culture conditions and OMV purification 
Bacteroides fragilis strain NCTC9343, Bacteroides thetaiotamicron ATCC 29148 and 
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Bacteroides vulgatus ATCC 8482 were obtained from the American Type Culture 
Collection, and B. fragilisΔPSA has been described previously (45). Bacteroides strains 
were grown anaerobically (80% N2, 10% H2, 10% CO2) at 37ºC in brain heart infusion 
broth (BD Biosciences) supplemented with 5 µg/ml hemin (Sigma) and 0.5 µg/ml 
vitamin K (Sigma). Salmonella enterica serovar Typhimurium (IR715), a nalidixic acid-
resistant strain of 14028, was a generous gift from A. Bäumler. S. Typhimurium were 
grown aerobically at 37°C in Luria-Bertani (LB) broth. For the induction of OMVs, 
Bacteroides strains were grown in minimal media, which consisted of RPMI 1640, no 
phenol red (Life Technologies) supplemented with 1% fetal bovine serum (Life 
Technologies), 8 mg/ml glucose (Sigma), 2.5 µg/ml hemin (Sigma) and 0.25 µg/ml 
vitamin K (Sigma). B. fragilis OMV isolation was performed as previously described 
(32). Briefly, electron dense layer-enriched B. fragilis (46) was grown in minimal media 
for 24 hr anaerobically. OMVs were recovered from the bacteria-free culture supernatant 
by ultracentrifugation, washed, resuspended in PBS and filtered through a 0.4 µm filter 
(Millipore) prior to treatment of cell cultures or oral gavage of mice.  
 
Experimental colitis 
WT (Atg16l1fl/fl Cd11c-Cre-/-), ATG16L1-deficient (Atg16l1fl/fl Cd11c-Cre+/-; 
Atg16L1ΔCD11c), ATG16L1 T300A, or Nod2-/- mice were orally gavaged with PBS or WT-
OMV (5 µg) every other day for one week prior to 2,4-dinitrobenzenesulfonic acid 
(DNBS; Sigma) administration. On day 7, mice were anesthetized with isofluorane, and 
rectal administration of 5% DNBS in 50% ethanol was applied through a 3.5F catheter 
(Instech Solomon), as previously described (32). Control groups received ethanol 
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(Sham). Briefly, a flexible silicone catheter was inserted 4 cm into the colon, and the 
mice were held in a vertical position for at least 1 min after rectal administration. Mice 
were monitored and weighed daily for the duration of the experiment. Upon sacrifice, gut 
tissue was harvested, fixed in neutral 10% buffered formalin, embedded in paraffin, 
sectioned and stained with hematoxylin and eosin (H&E). All histology was evaluated in 
a blinded analysis by two veterinarians using a comprehensive scoring system. 
Hematoxylin-eosin-stained slides were scanned and digitally scored using a while slide 
imaging system (Hamamatsu NanoZoomer Slide Scanner 2.0HT). Slides were read using 
software (Hamamatsu NanoZoomer Viewer NDP.View 2.3.1) to allow the use of a web-
based file-sharing platform. Colitis was classified into acute, chronic and chronic active, 
depending on the existence of vascular reaction (hyperemia, edema, hemorrhage). In 
addition, the predominant types of leukocytes in the infiltrates were considered 
(polymorphonuclear and/or mononuclear). The extension and the nature of the lesions 
allowed defining the distribution (focal, multifocal, locally extensive or diffuse) and the 
intensity (discrete, moderate, severe, transmural). Scoring was based on a modification of 
an approach described previously (47). Briefly, the number and distribution of mucosal 
polymorphonuclear cells as well as mononuclear cells and epithelial cell damage were 
scored from 0 – 4. The submucosa was scored for cellular infiltrates from 0 – 3 while the 
thickening and cellular infiltrates in the muscularis were scored from 0 – 2. All 
photomicrographs were captured using NanoZoomer Viewer NDP View 2.3.1 and scored 
using the same criteria by two people (P.B.E. and A.C.V.), including a comparative 
pathologist (A.C.V). 
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In vitro DC-T cell co-culture 
Co-culture of bone marrow-derived dendritic cells (BMDCs) and CD4+ T cells were 
performed as previously described (30, 32, 36). Briefly, BMDCs were generated from 
bone marrow progenitor cells isolated from femurs of WT or Atg16L1ΔCD11c mice in the 
presence of 20 ng/ml GM-CSF (Miltenyi) in complete RPMI media 1640 (10% fetal 
bovine serum, 50 U/ml penicillin, 50 µg/ml streptomycin, 2mM L-glutamine, 1mM 
sodium pyruvate, 1mM HEPES, and non-essential amino acids, and β-mercaptoethanol). 
BMDCs were pulsed with PBS, WT-OMVs (10 µg/ml), ΔPSA-OMVs (10 µg/ml) or pure 
PSA (50 µg/ml) for 18 – 22 hrs; OMVs with a protein content of 10 µg contain 50 µg of 
PSA. BMDCs were washed, and co-cultured with splenic CD4+ T cells at a ratio of 1:10 
(DC:CD4+ T cells) in the presence of 0.1µg/ml anti-mouse CD3 and 5 ng/ml of 
recombinant human TGF-β (Peprotech). After 3 – 5 days of co-culture, supernatants were 
collected for enzyme-linked immunosorbent assay (ELISA) analysis and cells stained 
with specific antibodies and a viability dye for analysis by flow cytometry. 
 
To generate monocyte-derived dendritic cell (MoDCs), human PBMCs were isolated 
from fresh whole blood the same day of harvest using Ficoll-Hypaque (GE Healthcare) 
gradient (density = 1.070 g/ml), followed by monocyte enrichment using the Human 
Monocyte Isolation Kit II (Miltenyi). For differentiation into MoDCs, monocytes were 
incubated with recombinant human IL-4 and GM-CSF (Peprotech) every two days in 
complete RPMI 1640 (5% human AB serum, 50 U/ml penicillin, 50 µg/ml streptomycin, 
2mM L-glutamine, 1mM sodium pyruvate, 1mM HEPES, non-essential amino acids, β-
mercaptoethanol). MoDCs were pulsed with PBS, B. fragilis OMVs or PSA for 18 – 22 
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hrs, washed, and co-cultured with syngeneic CD4+ T cells, isolated using the Human 
CD4 Isolation Kit II (Miltenyi), at a ratio of 1:10 (DC:CD4+ T cells) in the presence of 1 
mg/ml anti-human CD3 (eBiosciences) and 5 ng/ml of recombinant human TGF-β 
(Peprotech). After 6 days of co-culture, cells were restimulated with phorbol 12-myristate 
13-acetate (PMA) (Sigma) and ionomycin (Calbiochem) in the presence of GolgiPlug 
(BD Biosciences) for 4.5 hr, and stained with specific antibodies and a viability dye for 
analysis by flow cytometry. 
 
In vitro T cell suppression assay 
CD4+CD25+ Treg cells were purified from in vitro BMDC-T cell co-cultures using 
magnetic microbeads (Miltenyi). CD4+CD25- responder effector T cells (Teff) were 
isolated from mouse spleens, labeled with 2.5 µM CFSE for 10 min at 37ºC in the dark, 
washed, and incubated with Treg cells at various Treg:Teff ratios in the presence of 1 µg/ml 
anti-mouse CD3 (eBiosciences). Irradiated CD4-depleted mouse splenocytes served as 
antigen-presenting cells. Cultures were incubated for 48 and 72 hrs, cells were stained 
with specific antibodies and a viability dye, and analyzed by flow cytometry. Dilution of 
CFSE signal is a measure of proliferation, and inhibition of proliferation a measure of 
Treg activity. 
 
Isolations of cells from tissues 
Isolation of colon lamina propria (cLP) lymphocytes was performed, as previously 
described (30, 32, 36). Briefly, colons were cut open longitudinally, and luminal contents 
flushed with ice-cold PBS. Colons were cut into 1 cm pieces and incubated for 20 min in 
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10 mM dithiothreitol (Sigma) with gentle shaking, followed by two incubations at 20 min 
in 20 mM EDTA (Sigma). Supernatants were removed and remaining tissue was 
incubated in 1 mg/ml Collagenase D (Sigma), 0.25 U/ml Dispase (Roche), and 0.5 mg/ml 
DNase I (Worthington). Cells were filtered through a 70 µm cell strainer (BD Falcon) 
and separated by a 40%/80% (v/v) Percoll (GE Healthcare) density gradient. Cells were 
washed prior to staining for flow cytometry.  
 
MLN and spleens were processed by grinding tissues through 100 µm cell strainer (BD 
Falcon) to generate single cell suspensions. Splenic cells were treated with RBC lysis 
buffer (Sigma) and washed prior to staining for flow cytometry. 
 
Flow cytometry, intracellular cytokine staining, and ELISA 
Cells were incubated in 5% mouse serum for 15 min and stained for 20 min at 4ºC with 
either LIVE/DEAD fixable green or far red dead stain kit (Life Technologies), with 
empirically titrated concentrations of the following antibodies: PerCP-Cy5.5-conjugated 
anti-mouse CD4 (clone: RM4-5), PerCP-Cy5.5-conjugated anti-human CD4 (clone: 
OKT4), and/or PE-Cy7-conjugated anti-mouse CD4 (clone: RM4-5). For intracellular 
staining, cells were fixed and permeabilized with the Foxp3/Transcription factor buffer 
kit (eBioscience). Intracellular staining was performed using the following antibodies: 
FITC-conjugated anti-mouse IFNγ (clone: XMG1.2), PE-conjugated anti-mouse IL-10 
(clone: JES5-16E3), PE-conjugated anti-human Foxp3 (clone: PCH101), PerCP-Cy5.5 
anti-mouse IL-17A (clone: eBio17B7), APC-conjugated anti-mouse Foxp3 (clone: FJK-
16s), and/or APC-conjugated anti-human IL-10 (clone: JES3-9D7). All antibodies were 
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purchased from eBioscience. ROS detection was performed as previously described (35). 
Briefly, BMDCs were incubated with 1µM dihydroethidium (Life Technologies) for 30 
min at 37ºC in the dark. Cells were washed and acquired immediately. Cell acquisition 
was performed on a BD FACS Calibur (BD Biosciences) or Miltenyi MACSQuant 
(Miltenyi), and data was analyzed using FlowJo software suite (TreeStar). For ELISAs, 
cell supernatant from in vitro DC-T cell co-culture were collected and mouse IL-10 and 
IL-17A were measured using commercially available kits (eBiosciences). 
 
RNA isolation and quantitative real time RT-PCR 
BMDCs were harvested, washed, and immediately lysed in RLT buffer for RNA isolation 
using the RNeasy Mini Kit, according to manufacturer’s protocol (Qiagen). 1 µg of RNA 
was reverse transcribed using iScript cDNA Synthesis Kit, according to manufacturer’s 
protocol (Bio-Rad) and diluted to 10 ng/µl based on the input concentration of total RNA. 
 
Gene specific primers were designed using MacVector software and synthesized by 
Integrated DNA Technologies. Real-time PCR for the mammalian house keeping gene β-
actin was used to ensure that input RNA was equal among all samples. Real-time PCR 
was performed on cDNA using the ABI PRISM 7900 HT (ThermoFisher).  
 
Western blot  
BMDCs were washed with PBS and lysed with 1X RIPA buffer (EMD Millipore) with 
protease inhibitor cocktail (Roche). Protein concentration was determined using BCA 
protein assay (Pierce). Samples were analyzed on 4 - 20% Tris-Glycine gels (Novex) and 
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proteins were transferred to Immobilon-P PVDF membrane (EMD Millipore). The 
membrane was blocked in 5% nonfat dry milk and probed for α-PSA (1:1000) or α-
mouse β-actin (1:3000) (Cell Signaling) rabbit polyclonal antibodies with a horseradish 
peroxidase (HRP)-conjugated goat α-rabbit secondary antibody (1:5000) (KPL) and 
developed using LumiGLO chemiluminescent substrate (KPL). Chemiluminescent signal 
was detected with the Gel DocTM XR+ System (Bio-Rad).  
 
Statistical analyses 
Student’s t-test was used for pairwise comparisons. Survival curve was analyzed using 
the Grehan-Breslow-Wilcoxin test. One-way and two-way ANOVA with Post-hoc Tukey 
test were used for comparisons among one or two or more groups, respectively, using the 
GraphPad PRISM software. 
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Fig. S1. Vehicle treatment of WT and Atg16L1ΔCD11c DCs does not induce significant 
production of IL-10 among CD4+Foxp3+ Tregs.  
 
Representative flow cytometry plots of CD4+Foxp3+IL-10+ Tregs from DC–T cell co-
cultures with WT and Atg16L1ΔCD11c DCs treated with PBS (vehicle). Data are 
representative of at least 3 independent experiments. 
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Fig. S2 
 
Fig. S2. Purified PSA does not require ATG16L1 to promote suppressive Treg 
activity.  
(A) Representative histrograms measuring suppression of responder T cell proliferation 
by in vitro generated Tregs from WT or Atg16L1ΔCD11c DCs treated with PBS, B. fragilis 
WT-OMV, ΔPSA-OMV or purified PSA. (B and C) T cell suppression index of in vitro 
generated Tregs from WT or Atg16L1ΔCD11c DCs treated with (B) ΔPSA-OMV or (C) 
purified PSA at various Treg:Teff ratios. Cell proliferation was stimulated with αCD3. 
Error bars represent S.E.M. *p < 0.05. Data are representative of at least 2 independent 
experiments. 
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Fig. S3 
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Fig. S3. Atg16l1 fl/fl LysMCre DCs are unable to support B. fragilis OMV-induced  
IL-10 production. 
 
ELISA for IL-10 production from DC–T cell co-cultures with WT or Atg16l1fl/fl LysMCre 
DCs treated with PBS, B. fragilis WT-OMV, ΔPSA-OMV or purified PSA. Error bars 
represent S.E.M. ** p < 0.01. Data are representative of at least 2 independent 
experiments. 
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Fig. S4 
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Fig. S4. B. fragilis OMVs do not induce IL-10 production among Foxp3- type 1 
regulatory (Tr1) cells.  
 
Frequency of CD4+Foxp3-IL-10+ Tregs from DC–T cell co-cultures with WT or 
Atg16L1ΔCD11c DCs treated with PBS, B. fragilis WT-OMV, ΔPSA-OMV or purified 
PSA. Data are representative of 3 independent experiments.  
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Fig. S5 
 
 
 
Fig. S5. B. fragilis OMVs require Atg5 and Atg7 to promote IL-10 production from 
Foxp3+ Tregs.  
Proportions of IL-10 expression among CD4+ Foxp3+ Tregs following PBS, B. fragilis 
WT-OMV, ΔPSA-OMV or purified PSA treatment of (A) WT and Atg5fl/fl LysMCre or 
(B) Atg7fl/fl LysMCre BMDCs co-cultured with CD4+ T cells. Error bars represent S.E.M. 
* p < 0.05, **** p < 0.0001. Data are representative of at least 3 independent 
experiments. 
 
 
15 
 
  
Fig. S6 
 
 
Fig. S6. B. fragilis OMVs do not require canonical autophagy to promote IL-10 
production in Foxp3+ Tregs.  
The requirement of canonical autophagy was examined using (A) Ulk1-/- , (B) Fip200 fl/fl 
LysMCre or (C) Atg14 fl/fl LysMCre BMDCs treated with PBS, B. fragilis WT-OMV, 
ΔPSA-OMV or purified PSA, then co-cultured with CD4+ T cells. Measurement of IL-
10+ cells among the Foxp3+ Treg population by flow cytometry. Error bars represent 
S.E.M. Data are representative of at least 3 independent experiments. 
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Fig. S7 
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Fig. S7. B. fragilis WT-OMVs activate the LAP pathway.  
 
Quantification of LC3-GFP accumulation upon 2h treatment of BMDCs with PBS, B. 
fragilis WT-OMV, ΔPSA-OMV or purified PSA in Rubicon+/- or Rubicon-/- DCs. Error 
bars represent S.E.M. **** p < 0.0001. Data are representative of 3 independent 
experiments. 
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Fig. S8  
0 1 2 3 4
0
50
100
Pe
rc
en
t s
ur
vi
va
l
WT + PBS
WT + OMV
Atg16L1ΔCD11c + PBS
Atg16L1ΔCD11c+ OMV
*
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
Il1
0/
Il1
2 
tra
ns
cr
ip
t r
at
io
WT
DNBS:
Treatment: PBSOMV
Atg16L1ΔCD11c
PBS OMVPBS PBS
- + + - + +
*p = 0.057
A B
0
5
10
15
C
D
4+
 F
ox
p3
+  
IL
-1
0+
 (%
)
*
Genotype:
Treatment: PBS OMV OMVPBS
WT Atg16L1ΔCD11c
C
 
 
Fig. S8. B. fragilis OMV-mediated protection from colitis requires ATG16L1 in 
DCs.  
 
(A) Survival cure of WT and Atg16L1ΔCD11c mice orally treated with PBS or B. fragilis 
WT-OMV during DNBS colitis. Data are representative of at least 6 independent 
experiments, with 4 - 10 mice/group. * p < 0.05, Gehan-Breslow-Wilcoxon test. (B) 
MLNs isolated post-DNBS analyzed for Il10/Il12 transcripts, as assessed by quantitative 
real-time RT-PCR. Transcripts were normalized to β-actin. (C) cLP lymphocytes isolated 
post-DNBS analyzed for IL-10 production among CD4+Foxp3+ Tregs. Error bars represent 
S.E.M. * p < 0.05. Data are representative of at least 2 independent experiments, with 3-5 
mice/group. 
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Fig. S9 
 
 
 
Fig. S9. B. fragilis OMV-mediated protection is not due to an overall defect in Treg 
development in Atg16L1ΔCD11c mice under naïve conditions.  
 
Proportions of CD4+Foxp3+ T cells in (A) spleen, (B) MLNs and (C) cLP of WT and 
Atg16L1ΔCD11c naïve mice. Error bars represent S.E.M. ns, not significant. Data are 
representative of at least 2 independent experiments, with 3-5 mice/group. 
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Fig. S10 
 
 
 
Fig. S10. B. fragilis OMV-mediated protection is not due to an overall defect in Treg 
development in Atg16L1ΔCD11c mice during colitis.  
 
Proportions of CD4+Foxp3+ T cells in (A) MLNs and (B) cLP of WT and Atg16L1ΔCD11c 
mice orally treated with PBS or B. fragilis WT-OMV during DNBS colitis. Error bars 
represent S.E.M. ns, not significant. Data are representative of at least 3 independent 
experiments, with 3-5 mice/group. 
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Fig. S11 
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Fig. S11. CD4+IFN-γ+ populations are not significantly altered by B. fragilis WT-
OMV treatment during DNBS colitis.  
 
(A) MLN and (B) cLP lymphocytes isolated post-DNBS analyzed for IFN-γ production 
among CD4+ T cells, as assessed by flow cytometry. Error bars represent S.E.M. ns, not 
significant. Data are representative of at least 2 independent experiments, with 3-4 
mice/group. 
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Fig. S12 
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Fig. S12. OMV treatment of Atg16L1ΔCD11c DCs promotes IL-17A production. 
 
In vitro DC–T cell co-cultures with WT or Atg16L1ΔCD11c DCs treated with PBS or B. 
fragilis WT-OMVs and analyzed for IL-17A by (A) ELISA and (B) ICCS among 
CD4+Foxp3+ Tregs. Error bars represent S.E.M. **** p < 0.0001. Data are representative 
of at least 3 independent experiments. 
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Fig. S13 
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Fig. S13. Commensal and pathogen-derived OMVs differentially utilize ATG16L1 
in CD11c+ BMDCs. 
 
Frequency of (A) CD4+Foxp3+IL-10+ Tregs, (B) CD4+Foxp3+IL-17A+ T cells and (C) 
CD4+IFN-γ+ T cells from DC–T cell co-cultures with WT or Atg16L1ΔCD11c DCs treated 
with PBS, B. fragilis WT-OMV, ΔPSA-OMV, Bt-OMV, Bv-OMV, or S.Tm OMVs. 
Error bars represent S.E.M. *** p < 0.001, **** p < 0.0001. Data are representative of 3 
independent experiments. Bt, Bacteroides thetaiotamicron; Bv, Bacteroides vulgatus; 
STm, Salmonella enterica serovar Typhimurium. 
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Fig. S14 
 
anti-­PSA
anti-­β-­actin
WT-­OMV
10  µg/ml
PSA
50  µg/ml
WT Δ WT Δ WT Δ WT Δ WT Δ WT Δ WT Δ WT Δ WT Δ WT Δ
A
B
!
WT DC +PBS WT DC + OMV Atg16L1ΔCD11c DC + OMV
MHCII CD80 CD86
C D E
 
 
Fig. S14. Atg16L1ΔCD11c DCs are not impaired in uptake of B. fragilis-labeled OMVs.  
 
(A) WT and Atg16L1ΔCD11c BMDCs were pulsed with WT-OMVs at indicated time 
points and analyzed for uptake of WT-OMVs. Treated DCs were analyzed by western 
blot and probed for PSA and β-actin. Δ, Atg16L1ΔCD11c DCs. Data are representative of at 
least 4 independent experiments. (B) WT and Atg16L1ΔCD11c BMDCs were pulsed with 
Click-iT-labeled-Alexa Fluor 647 WT- or ΔPSA-OMV for 3 h and analyzed for uptake of 
OMVs among live CD11c+MHCII+ cells. Data are representative of at least 2 
independent experiments. (C to E) Representative histograms of MHC II (C), CD80 (D) 
and CD86 (E) expression among live, CD11c+ cells upon PBS and WT-OMV treatment 
of WT or Atg16L1ΔCD11c BMDCs. Data are representative of at least 4 independent 
experiments. 
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Fig. S15 
 
PBS WT-OMVΔPSA-OMV
0
100
200
300
400
Il1
b 
tra
ns
cr
ip
ts
 (r
el
 to
 β
-a
ct
in
)
WT Atg16L1ΔCD11c
**
***
PBS WT-OMVΔPSA-OMV
0
5000
10000
15000
Il6
 tr
an
sc
rip
ts
 (r
el
 to
 β
-a
ct
in
)
WT Atg16L1ΔCD11c
*
***
PBS WTOMV ΔPSA-OMV
0
50
100
150
Tn
fa
 tr
an
sc
rip
ts
 (r
el
 to
 β
-a
ct
in
)
WT Atg16L1ΔCD11c
* *
BA C
 
 
 
Fig. S15. Atg16L1ΔCD11c DCs display a hyper-inflammatory cytokine profile.  
 
Quantitative RT-PCR of (A) Il1b, (B) Il6, and (C) Tnfa in WT or Atg16L1ΔCD11c BMDCs 
treated with PBS, WT-OMV or ΔPSA-OMV, relative to the β-actin. Error bars represent 
S.E.M. * p < 0.05, ** p < 0.01, and *** p < 0.001. Data are representative of at least 4 
independent experiments. 
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Fig. S16  
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Fig. S16. Induction of CD4+Foxp3+IL-10+ Tregs in the colon during colitis is impaired 
in Nod2-/- mice. 
 
(A) cLP lymphocytes isolated post-DNBS analyzed for IL-10 production among 
CD4+Foxp3+ Tregs. (B) Proportions of CD4+Foxp3+ Tregs in MLNs of WT and Nod2-/- 
mice orally treated with PBS or B. fragilis WT-OMV during DNBS colitis. Error bars 
represent S.E.M. ** p < 0.01.  ns, not significant. Data are representative of at least 2 
independent experiments, with 4-5 mice/group.  
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Fig. S17 
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Fig. S17. TLR2 and NOD2 are involved in OMV-mediated induction of reactive 
nitrogen species (ROS), a feature of LAP.  
 
WT, Tlr2-/-, or Nod2-/- BMDCs were pulsed with WT-OMVs for 2h and ROS production 
was assessed by dihydroethidium (DHE), as measured for flow cytometry. Error bars 
represent S.E.M.  ** p < 0.01, *** p < 0.001, **** p < 0.0001. Data are representative of 
3 independent experiments. 
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Fig. S18  
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Fig. S18. ATG16L1 T300A transgenic mice are not protected from colitis by B. 
fragilis OMVs.  
 
(A) Frequency of IL-10 among CD4+Foxp3+ Tregs from DC–T cell co-cultures of WT and 
T300A BMDCs treated with PBS, B. fragilis WT-OMV, ΔPSA-OMV or purified PSA. 
(B) Weight loss and gross pathology, (C) colon length, (D) H & E sections, (E) and 
colitis scores of WT and T300A mice orally treated with PBS or B. fragilis WT-OMV 
during DNBS colitis. MLN lymphocytes isolated post-DNBS analyzed for (F) IL-10 and 
(G) IL-17A production among CD4+Foxp3+ Tregs, as assessed by flow cytometry. Error 
bars represent S.E.M. * p < 0.05, ** p < 0.01, **** p < 0.0001. Data are representative of 
at least 3 independent experiments, with 3 – 5 mice/group. 
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Table S1 
Sample ID Disease Status Genotype Sex Age Medications
CTL01 Normal T300 (AA) F 32 N/A
CTL02 Normal T300 (AA) F 40 N/A
CTL03 Normal T300 (AA) F 63 N/A
CD04 CD T300 (AA) M 57 N/A
CD05 CD T300 (AA) M 53 N/A
CD06 CD T300 (AA) M 39 N/A
CTL07 Normal T300A (GG) F 44 N/A
CTL08 Normal T300A (GG) F 68 N/A
CD09 CD T300A (GG) F 28 mercaptopurine (Purinethol); mesalamine (Apriso)
CD10 CD T300A (GG)
F 27
adalimumab (Humira); Bifidobacterium infantis (Align); multivitamin; 
Noreth A-ET Estra/FE Fumarate(Lo Loestrin FE PO), Omega-3 Fatty 
Acids-Vitamin E (fish Oil); Resveratrol
CD11 CD T300A (GG) M 37 N/A
CD12 CD T300A (GG) M 23 N/A
 
Table S1. Human subjects. 
 
Sample ID, disease status, ATG16L1 genotype, sex, age, and medications taken at time of 
blood collection. CTL, control; CD, Crohn’s disease; F, female; M, male.  
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